Organ specific tumor markers: What's new?

Indian Journal of Clinical Biochemistry

Volumn 27, Issue 2, 2012, Pages 110-120

  Vaidyanathan, Kannan ^a   Vasudevan, D M ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Immunohistochemical markers; Molecular markers; Proteomic markers

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARBOHYDRATE ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYCLIN E; CYTOKERATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; INHIBIN; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN; MUELLERIAN INHIBITING FACTOR; NEURON SPECIFIC ENOLASE; PROGESTERONE RECEPTOR; PROTEIN S 100; SQUAMOUS CELL CARCINOMA ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

BLADDER CANCER; BODY FLUID; BREAST CANCER; CANCER SCREENING; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; GENE EXPRESSION PROFILING; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; MICROMETASTASIS; MOUTH CANCER; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEOMICS; RADIOIMMUNOASSAY; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TESTIS CANCER; THYROID CANCER; UTERUS CANCER;

EID: 84864427863     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-011-0173-8     Document Type: Review

References (76)

1. Nair RR, Johnson JK. A dictionary to tumor markers and the methods of estimation. Advanced Biotech 2008; 22-32.
2. Maugeri-Saccà M, De Maria R. Translating basic research in cancer patient care. Ann Ist Super Sanita. 2011;47(1):64-71. Review.
3. Malati T. Tumour markers: an overview. Ind J Clin Biochem. 2007;22(2):17-31.
4. Ishii M. Limitations of clinical usefulness of tumor marker. Gan To Kagaku Ryoho. 1995;22(9):1139-45. Review.
5. Edge SB, et al., editors. AJCC cancer staging manual. New York: Springer; 2009.
6. Mostofi FK, Sesterhenn IA, Sobin LH. World Health Organization: International histological typing of tumors. 2nd edn ed. Berlin: Springer; 1998. p. 1-132.
7. Bhatt AN, Mathur R, Farooque A, Verma A, Dwarakanath BS. Cancer biomarkers-current perspectives. Indian J Med Res. 2010;132:129-49. Review.
8. Ren J, Cai H, Li Y, Zhang X, Liu Z, Wang JS, et al. Tumor markers for early detection of ovarian cancer. Expert Rev Mol Diagn. 2010;10(6):787-98. Review.
9. Van Gorp T, Cadron I, Vergote I. The utility of proteomics in gynecologic cancers. Curr Opin Obstet Gynecol. 2011;23(1):3-7. Review.
10. Thankamani V, Kumari TV, Vasudevan DM. Detection of herpes simplex virus type-2 DNA and human papilloma virus DNA sequences in cervical carcinoma tissue by molecular hybridization. J Exp Pathol. 1992;6(1-2):55-64.
11. Bast RC Jr, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, et al. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol. 1984;149(5):553-9.
12. Dawood MY, Ratnam SS, Teoh ES. Serum estradiol-17 beta and serum human chorionic gonadotropin in patients with hydatidi-form moles. Am J Obstet Gynecol. 1974;119(7):904-10.
13. Yachnin S. The clinical significance of human alpha-fetoprotein. Ann Clin Lab Sci. 1978;8(2):84-90. Review.
14. Beveridge RA. Review of clinical studies of CA 27.29 in breast cancer management. Int J Biol Markers. 1999;14(1):36-9. Review.
15. Lehner R, Enomoto T, McGregor JA, Shroyer AL, Haugen BR, Pugazhenthi U, et al. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol. 2002;84(1):120-5.
16. Mylonas I, Matsingou C, Käufl SD, Brüning A. Inhibin/activin betaE-subunit in uterine endometrioid adenocarcinoma and endometrial cancer cell lines: from immunohistochemistry to clinical testing? Gynecol Oncol. 2011;122(1):132-40. Epub 2011 Apr 20.
17. Mylonas I. Inhibin-a subunit expression in uterine endometrioid adenocarcinomas and endometrial cancer cell lines: a potential prognostic factor. Int J Mol Med. 2011;27(3):309-18. doi: 10.3892/ijmm.2010.586. Epub 2010 Dec 21.
18. Chang HL, Pahlavan N, Halpern EF, MacLaughlin DT. Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol. 2009;114(1):57-60. Epub 2009 Apr 8.
19. Holden JA, Snow GW, Perkins SL, Jolles CJ, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues. Mod Pathol. 1994;7(8):829-34.
20. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004;95(1):9-15.
21. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American society of clinical oncology. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33): 5287-312. Epub 2007 Oct 22. Review.
22. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer-European group on tumor markers recommendations. Tumour Biol. 2005;26(6):281- 93. Review.
23. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010;411(23-24):1869-74. Epub 2010 Sep 8. Review.
24. van Nagell J Jr, Donaldson ES, Wood EG, Goldenberg DM. The clinical significance of carcinoembryonic antigen in the plasma and tumors of patients with gynecologic malignancies. Cancer. 1978;42(3):1527-32. Review.
25. Fisher B, Redmond CK, Wickerham DL, Rockette HE, Brown A, Allegra J, et al. Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. Breast Cancer Res Treat. 1983;3(4):355-64.
26. Syrjänen KJ, Kosma VM. Hormone receptor levels related to histological parameters of tumor-host relationships in female breast carcinoma. J Surg Oncol. 1982;21(1):49-53.
27. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science. 1989;244:707-12.
28. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer. 1994;69(2):398-405.
29. Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7(6):340-7. Epub 2010 May 4. Review.
30. Kawauchi S, Furuya T, Ikemoto K, Nakao M, Yamamoto S, Oka M, et al. DNA copy number aberrations associated with aneu-ploidy and chromosomal instability in breast cancers. Oncol Rep. 2010;24(4):875-83.
31. Angelopopulou K, Diamandis EP, Sutherland DJA. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Can. 1994;58:480-7.
32. Tandon AK, Clark GM, Chamness GC, et al. Cathepsin D and prognosis in breast cancer. N Eng J Med. 1990;322:239-331.
33. Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, et al. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle. 2009;8(7):1062-8. Epub 2009 Apr 10.
34. Goncalves A, Bertucci F. Clinical application of proteomics in breast cancer: state of the art and perspectives. Med Princ Pract. 2011;20(1):4-18. Epub 2010 Dec 13. Review.
35. Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R, et al. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res. 2009;11(5):R71. Epub.
36. Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57(9):1242-55.
37. Lu J, Chang KL. Practical immunohistochemistry in hematopa-thology: a review of useful antibodies for diagnosis. Adv Anat Pathol. 2011;18(2):133-51. Review.
38. Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somsundaram K. BRCA1 and BRCA2 germline mutation analysis among indian women: identification of four novel mutations and high frequency occurrence of 185delAG mutation with independent origin. J Biosci. 2009;34(3):415-22.
39. Vaidyanathan K. Role of BRCA1/2 genes in hereditary ovarian cancer-IISc experience. Indian J Med Pediatr Oncol. 2007;27(1):21-2.
40. Vaidyanathan K, Ravi Shanker HM, Lakhotia S, Somasundaram K, Mukherjee G. Role of BRCA1 and BRCA2 genes in hereditary breast/ovarian cancer. Chin Med J. 2007;120(2):115-6.
41. Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasun-daram K, Mukherjee G. ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer. 2010;47(1):8-15.
42. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American society of clinical oncology. American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010;28(20):3388-404. Epub 2010 Jun 7.
43. Javadpour N. Multiple biochemical tumor markers in seminoma. A double-blind study. Cancer. 1983;52(5):887-9.
44. Ferro MA, Barnes I, Roberts JB, Smith PJ. Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. Br J Urol. 1987;60(1):69-73.
45. Jorda M, Morales A, Ghorab Z, Fernandez G, Nadji M, Block N. Her2 expression in prostatic cancer: a comparison with mammary carcinoma. J Urol. 2002;168(4 Pt 1):1412-4.
46. Fonseca GN, Srougi M, Leite KR, Nesrallah LJ, Ortiz V. The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma. Sao Paulo Med J. 2004;122(3):124-7. Epub 2004 Sep 16.
47. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3(94):94ra72.
48. Engstrom PF, Benson AB 3rd, Saltz L. National comprehensive cancer network. Colon cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003;1(1):40-53.
49. Bohanes P, Labonte MJ, Winder T, Lenz HJ. Predictive molecular classifiers in colorectal cancer. Semin Oncol. 2011;38(4): 576-87.
50. Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol. 2011;5(3):385-99.
51. Kruszewski WJ, Rzepko R, Ciesielski M, Szefel J, Zieliński J, Szajewski M, et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers. 2010;29(5):207-12.
52. Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund CA, Mäkelä O. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol. 1984;37(2):218-22.
53. Khoo SK, Mackay IR. Carcinoembryonic antigen in serum in diseases of the liver and pancreas. J Clin Pathol. 1973;26(7): 470-5.
54. Costello E, Neoptolemos JP. Pancreatic cancer in 2010: new insights for early intervention and detection. Nat Rev Gastroen-terol Hepatol. 2011;8(2):71-3. Review.
55. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 1987;55(5):513-6.
56. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol. 2001;12(6):745-60. Review.
57. Sudhoff HH, Schwarze HP, Winder D, Steinstraesser L, Görner M, Stanley M, et al. Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol. 2011; 268(11):1541-7.
58. Shivaraj G, Prakash BD, Sonal V, Shruthi K, Vinayak H, Avinash M. Thyroid function tests: a review. Eur Rev Med Pharmacol Sci. 2009;13(5):341-9. Review.
59. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011;135(5):569-77. Review.
60. Marsh DJ, Gimm O. Multiple endocrine neoplasia: types 1 and 2. Adv Otorhinolaryngol. 2011;70:84-90. Epub 2011 Feb 24. Review.
61. Bartram CR. bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia. J Exp Med. 1985;162(6):2175-9.
62. Delgado J, Pratt G, Phillips N, Briones J, Fegan C, Nomdedeu J, et al. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol. 2009;145(6):801-5. Epub 2009 Apr 15.
63. Ankathil R, Stephen J, Vasudevan DM, Kusumakumary P, Pillai GR, Nair MK. Prognostic significance of karyotype analysis in children with acute lymphoblastic leukemia. Hematol Oncol. 1992;10(6):339-44.
64. Hsi ED, Yegappan S. Lymphoma immunophenotyping: a new era in paraffin-section immunohistochemistry. Adv Anat Pathol. 2001;8(4):218-39. Review.
65. Maha A, Gan GG, Koh CL. Phenotype and TCR-gamma gene rearrangements in a Malaysian cohort of T-cell leukaemia/lym-phoma cases. Hematology. 2010;15(6):382-90.
66. Bosler DS, Douglas-Nikitin VK, Harris VN, Smith MD. Detection of T-regulatory cells has a potential role in the diagnosis of classical Hodgkin lymphoma. Cytometry B Clin Cytom. 2008; 74(4):227-35.
67. Budman LI, Kassouf W, Steinberg Jr. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J. 2008; 2(3):212-21.
68. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, et al. Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res. 2011;17(8):2417-25. Epub 2011 Apr 12.
69. Kim DH, Oh SJ, Oh CA, Choi MG, Noh JH, Sohn TS et al. The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol. 2011. doi:10.1002/jso.21919.
70. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-Positive gastric cancer and its impact on survival out-comes-a systematic review. Int J Cancer. doi:10.1002/ijc.26292.
71. Suresh K, Jayavardhanan KK, Vasudevan DM. Defective inter-leukin-2 R gene expression in gastric carcinoma patients. Immunol Invest. 1995;24(4):565-71.
72. Vasudevan DM, Vijayakumar T. Viruses in human oral cancers. J Exp Clin Cancer Res. 1998;17(1):27-31.
73. Pillay M, Vasudevan DM, Rao CP, Vidya M. p53 expression in oral cancer: observations of a South Indian study. J Exp Clin Cancer Res. 2003;22(3):447-51.
74. Vijayan KK, Remani P, Beevi VM, Ankathil R, Vijayakumar T, Rajendran R, et al. Tissue binding patterns of lectins in prema-lignant and malignant lesions of the oral cavity. J Exp Pathol. 1987;3(3):295-304.
75. Ravindran A, Vijayakumar T, Sudha L, Remani P, Vasudevan DM, Stephen J, et al. Chromosome abnormalities in squamous cell carcinoma of the human oral cavity. Neoplasma. 1990;37(2): 191-7.
76. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003;68:1075-82.